.png)
4 days ago
3
Trading information on Kenvue Inc., a consumer-health business spun off from Johnson & Johnson, is displayed on a screen during the company's IPO at the New York Stock Exchange in New York City, May 4, 2023.
Brendan Mcdermid | Reuters
Kimberly-Clark said on Monday it will acquire Tylenol-maker Kenvue in a deal valued at about $48.7 billion, creating a consumer goods giant.
Kenvue's shares were up 18% in premarket trading. Kimberly-Clark said it would buy all of the outstanding shares of Kenvue common stock in a cash-and-stock transaction.
Kenvue's shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held.
That implies a per-share deal value of $21.01, or an equity value of $40.32 billion, according to Reuters calculations.
